Nautilus Biotechnology, Inc.

NASDAQ:NAUT

2.61 (USD) • At close November 1, 2024
Bedrijfsnaam Nautilus Biotechnology, Inc.
Symbool NAUT
Munteenheid USD
Prijs 2.61
Beurswaarde 327,322,710
Dividendpercentage 0%
52-weken bereik 2.19 - 3.455
Industrie Biotechnology
Sector Healthcare
CEO Mr. Sujal M. Patel
Website https://www.nautilus.bio

An error occurred while fetching data.

Over Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is

Vergelijkbare Aandelen

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI

0.903 USD

2seventy bio, Inc. logo

2seventy bio, Inc.

TSVT

4.4 USD

Immatics N.V. logo

Immatics N.V.

IMTX

9.33 USD

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA

9.71 USD

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

18 USD

Cara Therapeutics, Inc. logo

Cara Therapeutics, Inc.

CARA

0.297 USD

Immunovant, Inc. logo

Immunovant, Inc.

IMVT

29.39 USD

908 Devices Inc. logo

908 Devices Inc.

MASS

3.46 USD

Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc.

VERA

43.82 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)